ITC – IMMUNO-model

Second Grant Call Opens on 1st May 2026 until 1st October 2026!

Super Admin — Fri, 24 Apr 2026 08:46:36 +0000

STSM: Short Term Scientific Mission

Visit to a host organization located in a different country than the country of affiliation by a researcher or innovator for specific work to be carried out and for a determined period of time.

VM: Virtual Mobility

Collaboration in a virtual setting among researchers or innovators within the IMMUNO-model COST Action, to exchange knowledge, learn new techniques, etc.

DC: Dissemination Conference

Funds an oral presentation by an Action Participant of the work of IMMUNO-model COST Action in a high-level conference fully organized by a third party, i.e. not organized nor co-organized by IMMUNO-model.

ITC: Inclusiveness Targeted Countries Conference

Funds an oral presentation of their own work within the scope of IMMUNO-model COST Action by an Action Participant affiliated to a legal entity located in an Inclusiveness Target Country / Near Neighbour Country in a high-level conference fully organized by a third party, i.e. not organized nor co-organized by IMMUNO-model.

YRI: Young Researchers and Innovators Conference

Funds a poster/oral presentation of their own work by a Young Researcher and Innovator (YRI = below 40 years old) in a high-level conference fully organized by a third party, i.e. not organized nor co-organized by IMMUNO-model.

Am I eligible? https://www.cost.eu/am-i-eligible/
Annotated Rules FAQ: https://www.cost.eu/cost-actions/annotated-rules-qa/

For details please visit: https://www.immuno-model.eu/mobility-grants/

STSM contact:
Grant Awarding Coordinator
Dr. Philippe Bertrand

Grant applications are open for Grant Period 4 (November 1st 2025-October 31st 2026)

Super Admin — Thu, 13 Nov 2025 15:33:40 +0000

STSM: Short Term Scientific Mission

Visit to a host organization located in a different country than the country of affiliation by a researcher or innovator for specific work to be carried out and for a determined period of time.

VM: Virtual Mobility

Collaboration in a virtual setting among researchers or innovators within the IMMUNO-model COST Action, to exchange knowledge, learn new techniques, etc.

DC: Dissemination Conference

ITC: Inclusiveness Targeted Countries Conference

YRI: Young Researchers and Innovators Conference

Am I eligible? https://www.cost.eu/am-i-eligible/
Annotated Rules FAQ: https://www.cost.eu/cost-actions/annotated-rules-qa/

For details please visit: https://www.immuno-model.eu/mobility-grants/

STSM contact:
Grant Awarding Coordinator
Dr. Philippe Bertrand

ITC report Nuno Rodrigues dos Santos

Super Admin — Fri, 26 Sep 2025 17:00:03 +0000

I was very pleased with the opportunity to present my team’s research work on the last day of the meeting. The findings I presented were freshly published in the Leukemia journal, so it was a great opportunity to showcase the work to the hematological malignancy community. It was also a great opportunity to meet again and discuss science with several collaborators in the field, coming from Spain and other countries.

Mobility Grants report for GP2

Super Admin — Tue, 11 Feb 2025 15:04:53 +0000

An initial budget of 28,000€ was proposed for GP2, to support up to 10 Short-term Scientific Mission (STSM) applications and some ITC and DC grants. VM grants support were added during the GP2 period.

A total of 12 STSM applications, 1 ITC, 3 DC and 2 VM were approved for this grant period. Some ITC and STSM applications were rejected.

The global budget spent is shown in the following table.

GP2
STSM (12)	25,581
ITC (1)	1,190
DC (3)	1,550
VM (2)	3,000
TOTAL	3,1321

Below are the applicants, their project with the location where they went, the length of their stay and a summary of the results.

Maria Urbanova

Implementation of the humanized mouse models as a tool for testing immunotherapy in pancreatic ductal adenocarcinoma.
Slovakia -> Norway, 2 weeks

Results: I gain hands-on experience in establishing humanized mouse models crucial for advancing PDAC cancer research at my home institute. I was also involved in working with other interesting methods, such as in vivo tumor imaging, patient-derived xenograft development, and cell transduction and sorting. The knowledge and skills I acquired at this laboratory will be highly beneficial for my future research and projects at my home institute.

" data-unfold-icon="" tabindex="0" role="button">View Results

Sumesh sasidharan

Immunotherapy-Induced Toxicity in Cardiovascular Disease: Translational Research Models and Techniques. France -> United Kingdoms, 2 weeks

Results: A major focus was to explore how preclinical cardiovascular immunology findings can be incorporated into my computational models. One of the significant outcomes of the STSM was the proposal for a collaboration between Prof. Maffia’s lab and my research at Aix-Marseille University with data sharing, which would enable me to incorporate their preclinical findings into my computational models. I prepared notes on the experimental techniques with a focus on standardizing these methods.

" data-unfold-icon="" tabindex="0" role="button">View Results

Mariangela Garofalo

T-cell phenotyping and evaluation of the immunomodulatory properties of oncolytic vaccines complexed with extracellular vesicles.
Italy -> Poland, 3 weeks

Results: Cancer-derived extracellular vesicles (EVs) loaded with oncolytic viruses (OVs) were produced and characterized. We evaluated the in vivo biodistribution of the EV carrying an oncolytic vaccine in melanoma models (IVIS Imaging System Lumina II). To confirm the efficacy spheroids and murine tissues were analyzed at the host institution via T-cell phenotyping. The results demonstrated that the novel formulations increased the infiltration of CD8+ cytotoxic T lymphocytes but more work is required.

" data-unfold-icon="" tabindex="0" role="button">View Results

Paula Martin Rubio

Establishment of patient-derived orthoxenograft mice models of lung metastases: a tool to test immunotherapies. Spain -> France, 2 weeks

Result: During my stay I had the opportunity to receive training on orthotopic lung surgeries in mice, thanks to Dr. Maraver’s team. I developed a detailed surgical protocol that outlines the entire orthotopic implantation procedure. This protocol, which includes audiovisual material gathered during surgeries, was reviewed by the team of Dr. Maraver and ensures accurate implementation of the technique. Our aim is to use these advanced models to test NK cell-based immunotherapies against lung metastases from gastrointestinal tumors

" data-unfold-icon="" tabindex="0" role="button">View Results

Lucia Juhasikova

Implementation of slice culture technique as a tool for pancreatic ductal adenocarcinoma therapy testing. Slovakia -> Austria, 1 month

Results: I have learned many methods like organotypic slice culture (OTSC). OTSC is a great model for modelling tumour microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) as it can very precisely simulate its TME in patient and mouse samples.

" data-unfold-icon="" tabindex="0" role="button">View Results

Laura DrndKova

3D co-culture system for pancreatic cancer immunotherapy modelling.
Slovakia -> Poland, 1 week

Results: I gained valuable skills in establishing 3D co-culture models with cancer cells and PBMCs (create and maintain 3D spheroids), integrate immune cells, and test new immunotherapy treatments. The knowledge and techniques acquired will directly support our ongoing projects in cancer immunotherapy.

" data-unfold-icon="" tabindex="0" role="button">View Results

Lukasz Kuryk

Assessment of oncolytic virotherapy in 3D cancer spheroid model.
Poland -> Italy, 1 month

Results: I have been trained on protocols for 3D culture and bioimaging with IVIS Lumina system. The 3D protocol will be transferred and implemented at the National Institute of Public Health in Poland, focusing on development of more efficacious therapy for mesothelioma, with oncolytic adenoviruses in combinations with PD-1 and CTLA4. Furthermore, joint grant application initiatives and publication are planned. The STMS activities brought new knowledge and protocols related to 3D spheroid mesothelioma model and bioimaging protocols for assessment of biodistribution of oncolytic viruses.

" data-unfold-icon="" tabindex="0" role="button">View Results

Marilina Garcia Aranda

Multicellular 3d Immunospheroid models to advance personalized treatment strategies in colorectal cancer. Portugal -> Spain, 3 months

Results: I gained hands-on experience with advanced 3D cell culture models with the development of mono-, double-, and triple-cultured cancer spheroids, as well as 3D multilayer tissue-engineered hydrogel models. I developed expertise in the fixation and preparation of spheroids for paraffin embedding, prior to immunohistochemistry and immunofluorescence studies. The efficacy of varying chemotherapy was evaluated. Planned follow-up activities include continued collaboration with the host lab at i3S (research funding, joint participation in research projects, co-authored publications).

" data-unfold-icon="" tabindex="0" role="button">View Results

Tina Kolenc Milavek

Visualisation of the tumour microenvironment in organoids using Imaging Mass Cytometry. Slovenia -> Netherlands, 2 months 1 week

Results: I learnt the Imaging mass cytometry (IMC) to determine spatial characteristics of a tissue and observe interactions between cells. IMC allows to determine changes in the interactions within the glioblastoma microenvironment in organoids. Understanding how cell interactions change after therapy will hopefully help us to unveil the mechanisms underlying therapy resistance.

" data-unfold-icon="" tabindex="0" role="button">View Results

Thanh Hoa Vo

Investigating Immune-Drug Interactions in Acquired Drug-Resistant and Sensitive Breast Cancer Models. Ireland -> Poland, 1 month

Results: Techniques for working with PBMC cells were effectively exchanged. The STSM facilitated efforts towards the standardization of protocols across institutions. A refinement of these protocols will help adoption by other researchers in the field of drug resistance to contribute to a standardized approach. A co-authored chapter on our protocols for the IMMUNO-model book is ongoing.

" data-unfold-icon="" tabindex="0" role="button">View Results

Agnieszka Maslanka

Investigating the infiltration of immune cells in mouse tumors using fluorescence microscopy. Poland -> Romania, 2 weeks

Results: I gain valuable knowledge and skills concerning tumor tissue preparation and processing, as well as immunostaining and image acquisition. As a young PhD student, I got the chance to learn from experts in the field, as well as expand my professional network and connect with other researchers interested in similar topics.

" data-unfold-icon="" tabindex="0" role="button">View Results

Milan Beljkas

New models for the development of dual HDAC/ROCK inhibitors as potential drugs to improve the efficacy and overcome the resistance of cancer immunotherapies. Serbia -> Estonia, 1 month

Results: Novel QSAR (Quantitative Structure-Activity Relationship) models were created for performing molecular docking studies to predict the activity of novel dual HDAC/ROCK inhibitors. I acquired knowledge in in Schroedinger Suite 2023 for molecular docking and artificial intelligence based QSAR machine learning with Python. 15 optimal candidates have been identified for predicted activity and key interactions with HDAC6, ROCK1 and ROCK2.

" data-unfold-icon="" tabindex="0" role="button">View Results

Marleen Ansems

COST CA21135 – IMMUNO-model – WG3: Solid tumors – models to study immunotherapy efficacy and toxicity in solid tumors, and validate biomarkers to monitor these effects. Netherlands -> Romania, 3 days

Results: I took part in the International Pathology Conference at the Victor Babeș Institute in Bucharest, Romania. I engaged in discussions with conference organizers and fellow participants, explored the institute, and attended presentations. Moreover, I disseminated information about our COST action, IMMUNO -model, to further build our network of Immune-Oncology researchers and facilitate connections.

" data-unfold-icon="" tabindex="0" role="button">View Results

Gianmarco Contino

COST Session in collaboration with COST Immunomodels.
2 days

Results: Presenting COST Action CA21135 at the EUSICA/INSICA Brain Conference was a successful endeavor, marked by significant interest and engagement from the attendees. The round table discussion further facilitated meaningful connections with potential collaborators, paving the way for future partnerships that will enhance the impact of our action. Moving forward, we remain committed to expanding our network and driving advancements in brain research through collaborative efforts.

" data-unfold-icon="" tabindex="0" role="button">View Results

Devrim Pesen Okvur

COST CA21135 – IMMUNO-model – WG1: In vitro and ex vivo cancer immunotherapy models – establishing basic protocols for immunotherapy response evaluation. Turkey -> Romania, 3 days

Results: Attending the conference made it possible to disseminate information about IMMUNO-model COST action to targeted groups like young researchers. Attendance was also disseminated through social media – LinkedIn and X (Twitter). I talked about the scope of COST actions in general and our COST action IMMUNO-model specifically. I delivered information about objectives, achievements, plans for the future and how to get involved. The LinkedIn post got 2158 impressions, 76 reactions, 1 comment and 2 reposts. Responders were from Turkiye, Netherlands and Romania.

" data-unfold-icon="" tabindex="0" role="button">View Results

Emanuela Senjor

Establishment of IMMUNOmodel Knowledge Hub.
2 months

Results: Almost all the proposed outcomes were produced. We are close to fulfil the CA objective of establishing and open-access database of experimental protocols of immuno-oncology models. Two tasks are still under work, as the IMMUNO-model Knowledge Hub not public yet. The protocol collection was planned to begin by the end of grant period 2. The task force will perform an internal test submission to check for any technical problems before we open the submission to the members of the CA. We plan to finish this by October, so we can start collecting protocols by the end of October/ beginning of November.

" data-unfold-icon="" tabindex="0" role="button">View Results

Marco Barreca

Omics Data Gathering.
Italy, 1 month

Results: During the Virtual Mobility period, a dedicated taskforce and I defined the main principles of dataset searching and curation. We laid the foundations for a larger project aimed at visualizing and analyzing publicly available omics datasets in the immuno-oncology field. These tools will enable researchers to easily access and organize relevant data, contributing to biomarker discovery and translational research.

" data-unfold-icon="" tabindex="0" role="button">View Results

Georgios Aindelis

Treatment of colon cancer cells with Lacticaseibacillus casei: induction of apoptosis and release of DAMPs associated with immunogenic cell death. 21^st Annual CIMT Meeting. Greece -> Germany, 3 days

Results: I had the chance to converse with experts on the field of immunotherapy, presenting my work and witnessing the innovative ideas of others. I also made acquaintances with researchers interested in our work, informed them about the goals of the IMMUNO-model COST Action and I am looking forward for an opportunity to further our cooperation with them in future joined studies.

" data-unfold-icon="" tabindex="0" role="button">View Results

Some statistics for mobility grants

Purple: COST member countries; Blue: ITC countries

Applicant’s country of origin by number.

Number of projects related to our 5WGs.

Host organizations’ country by number.

Average cost/day or week of mission

Gender balance

Some statistics for DC mobility grants

Purple: COST member countries; Blue: ITC countries

Applicant country

Host country

Gender balance

WG related to the projects

VM statistics GP 2, 2 applications

Gender F/M = 1/1

ITC statistics GP2

1 Sender Greece

1 Host Germany

Gender balance M 1

WG relation: WG1/5

Mobility Grants report for GP1

Super Admin — Tue, 11 Feb 2025 11:38:22 +0000

An initial budget of 22,050€ was proposed for grant period 1, to support up to 8 Short-term Scientific Mission (STSM) applications. And 3,000€ euro for two Inclusiveness Target Country (ITC) grants and 3,000€ euro for two Dissemination (DC) grants were also defined.

A total of 9 STSM applications were submitted for this grant period.

The first one was cancelled early by the applicant due to a sudden unavailability of one supervisor for the expected dates of the application. This application was postponed for Grant Period 2 (GP2).

Another application was accepted but a problem of visa was raised and the applicant was not able to go at the expected dates of the application. This application will probably be reported for GP 2.

A total of 7 STSM applications were finally gone to completion with successful results. The global budget spent was: 12,280€.

A single ITC application was accepted for a budget of 510 euros.

Below are the applicants, their project with the location were they went, the length of their stay and a summary of the results. ITC application is in blue background.

Emanuele Azzoni, Ph.D

Transplantation of fetal-restricted hematopoietic progenitors into new born mice to assess their lineage contribution. Milano -> Paris, 1 week.

Results: Transgenic mice embryos (Cdh5-CreERT2::R26-EYFP) were produced in a small quantity compared to expected results but an ongoing collaboration is established to continue the project. This STSM also resulted in several exchange of knowledge with meetings/seminars to generate ideas for future collaborations.

" data-unfold-icon="" tabindex="0" role="button">View Results

Cristiana Barone, Post doc.

Transplantation of fetal-restricted hematopoietic progenitors into new born mice to assess their long-term repopulation ability. Milano -> Paris, 1 week

Results: Transgenic mice embryos (Cdh5-CreERT2::R26-EYFP) were produced in a small quantity compared to expected results and ongoing collaboration is established to continue the project. The applicant learnt how to make intravenous injection to new born pulp, a specific knowledge from the host institution. The host lab was highly interested by the imaging facilities master at the sending institution for future collaborations.

" data-unfold-icon="" tabindex="0" role="button">View Results

Carles Bofill Bonet, 3rd year Ph.D

Enhancing local administration of TIMP-3 protein to avoid cell proliferation in cancer. Barcelona -> Angers (FR), 1 month

Results: mRNA TIMP-3 (immune response regulator) nanoparticles have been successfully incorporated into the hydrogel/poloxamers without altering their properties such as mRNA releasing capabilities. The particles are internalized by cells were expression of TIMP-3 was lower than expected. Seminars were organized to share results and knowledge.

" data-unfold-icon="" tabindex="0" role="button">View Results

Ana Borges, 1st year Ph.D

Dissect the tumor microenvironment to battle cancer radioresistance and immune escape. Porto -> Paris, 1 month

Results: A proof of concept that the modulation of immune-mediated radioresistance could constitute a novel therapeutic strategy for treatment of TNBC was established, using 3D preclinical cancer models. Data on 3D preclinical models were collected to establish open access standardized protocols. Another mission is planned to continue this work.

" data-unfold-icon="" tabindex="0" role="button">View Results

Flavia Castro, Ph.D

Unveil the therapeutic combination of IFN-gamma and chitosan/poly(γ-glutamic acid) nanoparticles for breast cancer treatment.
Porto -> Pamplona, 1 month

Results: She learn immune-phenotyping technique using an Imaging Systems, to analyse and integrate all the data collected, establish a cross-interdisciplinary international collaboration, and to bring the knowledge at i3s once the same equipment will be operational. A manuscript is in preparation. A seminar was planned at her Institution about the technique learnt. Receiving a PhD student from the host institution is planned as well as a grant application for funding.

" data-unfold-icon="" tabindex="0" role="button">View Results

Jelena Grahovac, Ph.D

Testing the anti-tumor NK cell activity in patient-derived pancreatic cancer culture in the microfluidic chip device. Belgrade -> Ljubljana, 1 week

Results: A proof of principle for microfluidic chip setup suitable for live imaging by confocal microscopy was established and evaluation of infiltration potential and cytotoxicity of engineered NK cells in pancreatic cancer spheroids derived from a patient. In data collection was planned during Dr Perišić Nanut’s visit to Serbia to have preliminary findings for a joint funding application

" data-unfold-icon="" tabindex="0" role="button">View Results

Milica Nanut, Ph.D

Analyzing the expression and main interacting partners of cystatin F in pancreatic ductal adenocarcinoma. Ljubljana -> Belgrade, 1 week

Results: Patient tissue material were analyzed and data were obtained on the level of cystatin F mRNA expression, its presence and spatial relations to other target peptidases within the tumour microenvironment as well as its molecular form. The best approach for modulation of cystatin F function wil be selected to contribute to get preliminary data necessary for gathering data for a joint grant application. During the stay seminars were organaised.

" data-unfold-icon="" tabindex="0" role="button">View Results

Ines Pinto, 1st year Ph.D

Nanoparticles for CAR T cell manufacturing: a potential gene delivery platform
Coimbra-> EACR conference – Barcelona, Poster

Results: The applicant established connections with Dr. Tyler Jacks (MIT, USA, CRISPR-Cas9 technology) for cancer immunotherapies, The Mimetics (Netherlands, startup with 3D culture cancer models). The attendance at the EACR Conference was a crucial step in advancing her career and expertise in cancer immunotherapy and had a positive impact on the IMMUNO-model COST Action by increasing its visibility.

" data-unfold-icon="" tabindex="0" role="button">View Results

Some statistics for mobility grants

Purple: COST member countries; Blue: ITC countries

Applicant’s country of origin by number.

Host organization’ country by number.

Number of projects related to our 5 working groups.

Gender balance

Europe map presentation of the STSM exchanges (from COST map countries by types)

Short report of ITC Grant Ines Pinto

Super Admin — Mon, 13 Jan 2025 11:56:37 +0000

Ines Pinto, 1st year of PhD, received ITC grant and attended EACR conference 2023 in Torino, Italy. She presented the poster entitled Nanoparticles for CAR T cell manufacturing: a potential gene delivery platform.

The applicant established connections with Dr. Tyler Jacks (MIT, USA, CRISPR-Cas9 technology) for cancer immunotherapies and The Mimetics (Netherlands, startup with 3D culture cancer models). The attendance at the EACR Conference was a crucial step in advancing her career and expertise in cancer immunotherapy and had a positive impact on the IMMUNO-model COST Action by increasing its visibility.

Grant applications are open for Grant Period 3 (November 1st 2024-October 31st 2025)

Super Admin — Mon, 09 Dec 2024 16:09:27 +0000

STSM: Short Term Scientific Mission

Visit to a host organization located in a different country than the country of affiliation by a researcher or innovator for specific work to be carried out and for a determined period of time.
First call: November 1st 2024 – April 30th 2025

VM: Virtual Mobility

Collaboration in a virtual setting among researchers or innovators within the IMMUNO-model COST Action, to exchange knowledge, learn new techniques, etc.

DC: Dissemination Conference

ITC: Inclusiveness Targeted Countries Conference

YRI: Young Researchers and Innovators Conference

Am I eligible? https://www.cost.eu/am-i-eligible/
Annotated Rules FAQ: https://www.cost.eu/cost-actions/annotated-rules-qa/

For details please visit: https://www.immuno-model.eu/mobility-grants/

STSM contact:
Grant Awarding Coordinator
Dr. Philippe Bertrand

Report on the outcomes of ITC Conference Grant Georgios Aindelis

Super Admin — Mon, 04 Nov 2024 17:00:37 +0000

ITC Grant Conference: 21st Annual CIMT Meeting, Mainz, Germany
Start and end date: 15/05/2024 to 17/05/2024
Candidate: Georgios Aindelis, Democritus University of Thrace, Department of Molecular Biology and Genetics, Alexandroupolis, Greece

Contribution details

Title of the presentation: Treatment of colon cancer cells with Lacticaseibacillus casei: induction of apoptosis and release of DAMPs associated with immunogenic cell death
Type of the presentation: Poster

Outcome of the conference participation

My participation in the 21st Meeting of the Association for Cancer Immunotherapy was a significant contribution to the development of my scientific career. During its course, my PI Prof. Katerina Chlichlia, who was also in attendance and I had the opportunity to witness the advancement being made in various fields of immunotherapy and the innovative research conducted towards the understanding and development of immunotherapeutic regimens. In addition, our work, presented as a poster in the Meeting during the session Improving Immunity, gained the attention of various participants who showed a keen interest in the bioactive properties of the probiotic strain utilized in our lab. Each one of them, according to their expertise, was able to offer their insight and critique on our research which is already being evaluated in the context of our work and will, without a doubt prove to be indispensable when designing our future experiments and possible additions in our studies. Furthermore, throughout the Meeting I had the chance to meet and converse with participants from industry and familiarize myself with novel protocols, techniques and cutting-edge, state of the art instruments, capable of greatly enhancing and expanding the scope of the research conducted in our lab. Finally, Prof. Chlichlia and I had the opportunity to establish contacts with other colleagues, from various research institutes, including but not restricted to Dr. Claudia Paret and Prof. Dr. Viktor Umanski and we are now considering the possibilities for future collaborations, either for me individually or our research group as a whole. Overall, my trip to Mainz and my participation in the CIMT Annual Meeting have given me a unique avenue to not only present my work and receive important feedback that will help me greatly in advancing my studies, but also appreciate the innovative ideas explored in the field of immunotherapy and find among the Meeting’s participants researchers and industry scientists for possible future collaborations.

Extension of grant applications deadlines!!!

Super Admin — Tue, 17 Sep 2024 08:46:18 +0000

Members of the IMMUNO-model COST Action are informed that applications for grants (STSM, ITC, DC, VM) have been extended.

New applications must be planned between 23 September 2024 up to 21 October 2024.

The final report must be submitted before 23 October 2024.

Members interested in applying please find bellow the documents to fill out.

For more information please contact Grant Awarding Coordinator philippe.bertrand@univ-poitiers.fr.

1st Call for ITC Applications – Grant Period 2, 01 November 2023 – 31 October 2024

Super Admin — Thu, 23 Nov 2023 09:58:30 +0000

The 2nd Call for ITC Applications will cover the Grant Period from November 1st, 2023 to October 31st, 2024, included.

Application deadlines

November 1st 2023 – June 30th 2024: Application for ITC open
Ongoing: selected candidates will be notified
June 30th 2024: deadline for submission of last ITC applications
September 15th 2024: deadline for the conclusion of ITC activities, including ITC reports
The last ITC submission will be June 30 2024.

Please follow this link for further details on the call: ITC Application Procedure

Feel free to share the call in your local network!

ITC contact:
Grant Awarding Coordinator
Dr. Philippe Bertrand